Data from the study showed that exa-cel prevented vaso-occlusive crises in all but 1 of the 30 evaluable patients for at least 12 months. Exagamglogene autotemcel (exa-cel; Casgevy) prevented ...
Fulcrum Therapeutics (NASDAQ:FULC) executives highlighted what they described as strong physician interest and encouraging clinical signals from the company’s PIONEER study in sickle cell disease ...
A Pfizer drug designed to address a severe problem associated with sickle cell disease failed to beat a placebo in a Phase 3 clinical trial. It’s the latest setback for Pfizer in this inherited blood ...
Most individuals living with sickle cell disease who presented to the emergency department with a pain crisis, known as vaso-occlusive crisis (VOC), were not triaged appropriately according to ...
The analysis emphasizes the association between vaso-occlusive crisis frequency and health care costs, which are inflated largely due to inpatient visits. Vaso-occlusive crises (VOCs) are a common ...
Most individuals living with sickle cell disease who presented to the emergency department with a pain crisis, known as vaso-occlusive crisis (VOC), were not triaged appropriately according to ...
Please provide your email address to receive an email when new articles are posted on . Lactated Ringer solution is the preferred volume resuscitation fluid for patients with sickle cell disease who ...
The analysis included 66 visits: 23 and 43 visits were assigned emergency severity index 2 and 3. HealthDay News — A majority of patients with sickle cell disease (SCD) with vaso-occlusive crisis (VOC ...
SAN DIEGO — A newly approved gene therapy product for sickle cell disease, lovotibeglogene autotemcel (lovo-cel, marketed as Lyfgenia), led to durable disease remissions for up to 5 years and almost ...
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending a CRISPR gene editing-based treatment for severe sickle cell disease (SCD). The regulator said ...
Please provide your email address to receive an email when new articles are posted on . Children with beta thalassemia achieved transfusion independence after being treated with exa-cel. Children with ...
* GLOBAL BLOOD THERAPEUTICS INC - AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF INCLACUMAB * GLOBAL BLOOD THERAPEUTICS INC - GBT WILL BE RESPONSIBLE FOR ALL DEVELOPMENT, MANUFACTURING, AND ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results